Business Wire · Jul 2026
Deep Genomics named Thong Q. Le chair of its board, with Chip Baird moving to chair the audit committee; the company said Le will help guide its next phase of growth and clinical pipeline progress.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Deep Genomics Inc. is a private Toronto-founded AI-first TechBio/biotechnology company developing genetic medicines. It combines computational biology, machine learning, RNA biology, automation, and experimental data to discover and develop therapeutics for genetically defined diseases. The company has been transitioning from a platform company toward a forward-integrated biopharmaceutical company.
Primary product
The Biological Foundation Model (BioFM) Platform, including BigRNA and related models such as REPRESS, evolved from the AI Workbench. It combines AI model development, fit-for-purpose biological datasets, lab-in-the-loop workflows, screening technologies, and software systems to decode RNA biology, identify therapeutic targets, and design RNA/oligonucleotide medicines.
Founded
2014
Headquarters
480 University Avenue, Suite 1300, Toronto, Ontario M5G 1V2, Canada
Team size
80–90 (LinkedIn-derived estimate; another database reports 101–250)
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
AI-enabled drug discovery, RNA therapeutics, computational biology, genetic medicines
Offices
480 University Avenue, Suite 1300, Toronto, Ontario M5G 1V2, Canada
1 Canal Park, Suite 300, Cambridge, Massachusetts 02141, USA
Funding
People & investors
Leadership
Chief Executive Officer
Founder, Chief Innovation Officer, and Board Member
Radu Dobrin
Chief Technology Officer
Chief Scientific Officer
Joel Shor
VP and Head of Machine Learning
Work & culture
Public materials describe a multidisciplinary, collaborative environment spanning machine learning, software engineering, computational biology, molecular biology, chemistry, and drug development. The company emphasizes a shared understanding of AI, software engineering, and RNA biology, with teams in Toronto and Cambridge. Public employer evidence is limited and third-party ratings are mixed.
Work style
Hybrid
Visa sponsorship
Limited
Compensation
A current Toronto Senior Research Scientist, Machine Learning listing gave a base salary range of C$175,000–C$200,000, plus competitive compensation and meaningful equity; U.S. compensation may differ. Historical U.S. immigration records show one green-card certification and no recent H-1B LCAs, so sponsorship should be treated as role- and location-dependent.
Benefits
Health, vision, and dental coverage for employees and families
Employee and family assistance program
Meaningful stock ownership
Product & market
Pricing
No public list pricing or self-serve pricing found. The apparent model is enterprise biopharma collaboration, co-development, milestone economics, and potential licensing rather than a conventional software subscription.
Differentiators
- —Integrated AI, biological data, software, automation, and experimental validation rather than a standalone prediction tool
- —Focus on RNA biology and genetically precise medicines
- —BigRNA/BioFM foundation-model approach for decoding RNA biology and designing therapeutics
- —Lab-in-the-loop model development and fit-for-purpose datasets
- —Forward integration into proprietary therapeutic programs
- —Large-scale prediction across genetic variants, RNA mechanisms, and candidate compounds
Technology
BigRNA
Scale & contact
Estimated revenue
$1M–$10M; one third-party estimate is approximately $5M annually, not company-reported
Estimated monthly visits
9.2K
Traffic estimate as of Jun 2026
Latest news
Deep Genomics · Oct 2025
Deep Genomics added Thong Q. Le and Paul Sekhri to the board, emphasizing strategic life-sciences and deal-making experience as the company advances AI-powered genetic medicines.
Deep Genomics · Jun 2025
The company appointed Vic Myer as chair and Richard Scheller to its Scientific Advisory Board to support AI-driven genomic R&D and drug discovery.
Deep Genomics · May 2025
Deep Genomics announced REPRESS, a new model predicting miRNA binding and mRNA degradation from sequence, and released it for non-commercial use via GitHub.
Open Positions
2 jobs at Deep Genomics
Principal Research Associate
On-siteCambridge, MA4d ago
On-site
Full-time